Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
IPIX has updated their website to remove all references to Kevetrin.
But shouldn't K be in the hands of SOMEONE who could check out further if it has great potential for cancer treatment?
If it is not IPIX, so be it, but there is a world of patients that would like to know all possible drugs are being tested to the fullest.
I would have thought some of those Italian researchers would have liked to acquire K for further study and possible commercialization.
Why didn't we give K to the BioMed guys - they would know how to move it forward one way or another as they have shown themselves true businessmen which we have yet to see out of IPIX.
I don't see where IPIX spent $1 on K over the last 5 or 6 years.
So does it just go to the waste bin - No other pharma wants to pick it up though it showed vast potential?
A drug shouldn't start it;'s patent life until it reaches the first revenue. They system is set up to inhibit the development of new drugs instead of promoting it.
The Cancer Research Center isn't going to jump on it for further study or are they more interested in keeping their jobs going by never finding a cure?
Read today that someone dies of sepsis every 2.8 seconds globally. Thought that Brilacidin - ABSSSI was supposed to be able to work against sepsis better than anything out there at the current time.
And to think that it has been sitting on the shelf for what, 5 years or more, due to a lack of funds to take it thru a P3 for about 3000 patients per the FDA guideline to IPIX. I am not sure if all the statements in this paragraph are exactly true but I do believe they are what I have heard over the years.
So why hasn't it at least been given to all serious cases for Compassionate Use since nothing else works? Why hasn't some government or medical organization come thru with the couple of million dollars or so to get the P3 done?
This is why this investment has been so damn bothersome. We see areas where many, many lives could be saved and yet no funds for a trial that IMO is totally beyond belief as to the numbers needed to come to a decision
I won't get political with this post but think of the funds that are completely wasted that would have been able to be spent on this trial and tens of thousands of lives may have been saved.
I feel Brilacidin and Kevetrin have the ability to save so many lives and yet for a few dollars we sit at nearly a standstill. The current work on viruses is nice but it is a far cry from the attention these 2 drugs deserved from the medical community iMO.
Didn't we also grant rights to Brilacidin Fungal uses to some outfit?
Another advantage of a nebulizer:
Probably 75% or more of Americans could figure out how to use it.
Inhaled delivery system via a nebulizer is the ideal delivery system IMO because it
1) Puts Brilacidin directly into the lungs to work against symptoms brought about by viruses
2) It's anti-inflammatory properties help diminish the effects of the viruses but also should work tremendously on many, many lung conditions such as COPD.
3) Not sure of this but could also possibly allow Brilacidin to spread throughout the body to help in many other areas.
4) May allow most people to carry a nebulizer in their pocket, purse, car, etc as an immediate aid when battling many, many health conditions.
What is the biggest fear that most of us longs have had concerning clinical trials for Brilacidin?
IMO it is that the FDA would screw with the trial parameters (as they did in our recent P2 for B-Covid) and leave no path for the trial to possibly succeed.
But with the B-Nasal viral spray, the testing in labs will have been done by the govt (NIAID), the delivery system would have been designed by the NIAID, and the dosage would have been determined by the NIAID. They have already targeted the spray to be used for Covid in the very early stages of it so that is one area we don't have to worry about. Basically, ALL the parameters of the P2 will have been developed by the NIAID and I am sure they would by severely upset should another agency try and make them look bad by not running the trial per their specifications.
Thus, I like our chances for the spray P2 to succeed.
A good friend brought to my attention that the actual poster at the military convention this week states in the Discussion/Conclusion section the following:
"Ongoing efforts are focused on dosing strategies for brilacidin to improve in vivo effectiveness in the form of a nasally-delivered countermeasure."
Please note that the ongoing efforts are focused on IN VIVO effectiveness so the spray has been given to either animals or humans and they are now maximizing the strategy of how strong to make the spray. IN VIVO is quite a step forward from in vitro. I know MackG already pointed this out on this board but it definitely needed repeating as it is a major step forward for B.
I had heard that the government has the rights to all medical uses of marijuana so why couldn't they pay IPIX a quite handsome fee or some other similar revenue generating plan for IPIX while the government gets pricing of it extremely low and have the rights to all its antiviral properties and uses? Win win situation.
I need to see IPIX succeed in the share price by the end of next year. I am praying they can make that come to pass.
Wish I had more faith in the medical community, the government medical organizations, Leo getting things done, and the anti's not keeping their boots on our necks.
Waiting and hoping while the science keeps showing itself stronger and stronger.
I just mentioned the name of the IPIX employee as I hadn't seen it before. What I really found interesting in the PR was the following:
1. Government studies of B are far beyond the stage I thought they were. If they are already trying to fine tune it as a nasal spray then they have already determined that it is the "go to" broad spectrum antiviral they have been seeking. If not, why already be studying delivery methods?
2. The nasal spray, once perfected, could allow B to be used for many anti-inflammatory lung applications and other anti-inflammatory uses IMO and if we decide to sell or partner w/ a BP it will greatly add to the value we get from such BP. Should also allow them to bring it to market extremely quickly.
3. Don't know if B lends itself to a nasal spray that would be used by most everyone around the world on a preventative basis due to cost but if it could stop many, many of the viruses and costs associated with them and it does become a common household medication it could be maybe the greatest revenue drug the world has seen. This is not saying it will happen, just that it is something to think about that could be a slight possibility.
4. They found it effective against a number of non-enveloped viruses as well as enveloped viruses. Another major expansion of possible applications.
5. They already know it is safe and are now trying to determine the most efficient dosage to put in the nasal spray delivery system.
6. It obviously has been brought to the top level of mgt in all the governmental medical communities by now.
7. There is a great need NOW for this nasal antiviral and Fauci and crew will not be able to bury it in favor of their BP cronies.
I now do not believe we will hear about a great amount of money being given to IPIX for further B development as we have nobody that could move it any further down the line (unless DeGrado did it in his UCSF lab) and I would have assumed over the last couple of years that they already have tested B against most viruses at his lab). Instead, we know that the government is progressing at full speed ahead on the ability to bring B to our military.
My only concern is that everything will be kept secret until major advancement is made on the nasal spray and that means we could be in for a dry spell of news that plays into the anti-IPIX hands.
All in all, IPIX continues to show itself to be the potential world-beater most of us longs believe it will become. Only down side is the time to get to the point when our investment becomes somewhat positive. That could still be sometime away but then our Bea-Med investment might come thru a bit quicker than I first expected. That is an impressive new level of technology they are bringing to the world.
So Kyle Weston is the name of the Business Development manager for IPIX? Other than Harness and Leo there is only one other employee I believe and he is listed as an IPIX employee in your post.
Here is an article on TIPs (therapeutic interfering particles) written by the main researcher (Weinberg) at the Gladstone lab located at UCSF.describing how TIPs work.
http://weinbergerlab.ucsf.edu/therapeutic-interfering-particles
I would love this product described to be B but I don't believe it is per this article.
3 1/2 years since that article came out. EMA moves about as fast as FDA - both about useless.
Thank you for that strong affirmation of Leo. Means a lot to me.
Why the need for a clinical trial as they are very costly, timely, and subject to administrative BS as we saw in the B-Covid trial?
Why not give the drug to a number of patients with various viruses that B showed a positive effect on in the 20+ in vitro tests in the lab on a Compassionate Use basis as was done w/ B-CV and see if there is a general positive acceptance? That would take very little time, money, and effort and results would then make a clinical trial worthwhile.
Most areas outside medicine that actually care about costs do such trial tests all the time.
GMU, a Regional Bio Lab, identified B as a possible prophylactic for Covid in 2020 and here we are in the middle of Q3 '22 and still nothing has been done to forward this research????
I sure would love to have had the work schedule and results driven management requirements of these governmental agencies when I was working.
I am sure there are Covid victims from the last year and their families that are even more upset with this lack of drive to find a solution that far surpasses IPIX stockholders degree of frustration.
Mgt should either shit or get off the pot. As for the last 3 years I seem to have had about as much to do with running the company as they did and I haven't done a damn thing.
Pisses me off to no end that I invested over $60K about the same time the CEO invested (loaned) the company $95K or so per the quarterly report and I paid 10 cents per share and he got them for 7 cents + 18% dividend on his investment.
No wonder they have not been overly eager to move the company forward, they slowly bleed it dry and then take it over for next to nothing and then follow up on the offers that have been brought to them, which I have heard happened but have no proof as to that matter.
We know we have the goods. We know we are in deep crap as to financing and as a result should a good offer come it will take away most of the company but if it allows the current investors to at least get their investment back and possibiy even make a little then they should be chasing after whatever is brought to the table.
Of course, when you are making 18% on your money who gives a damn, right?
I'd have to classify me as a hostile investor at the current time with the hope that I can vote on throwing out the entire management and BOD team.
Great news, stock ends down for the day. Same old story for the past 7 years or so - but God forbid anyone say that the stock is being controlled by hedge funds.
Leo recognized he needed help in this area and that is the reason for the additional employee earlier this year, a person experienced in business development with experience in dealing with BP.
The Payer Analysis announcement that it was being performed was put out by IPIX. If I remember correctly, it was in a filing, most likely the end of year filing.
I hope now IPIX gets a good partner for OM. I believe they could do it alone but since OM is the smallest revenue generator of all of B's potential applications, let's get hooded up with a good BP that will be able to move the ball forward much, much quicker than IPIX alone. Don't lose sight of the forest for the trees.
The major benefit from the OM application IMO is that once B is approved for it follow on applications for B should go much quicker and smoother.
IBD will absolutely dwarf OM potential and the anti inflammatory applications, not to mention the broad spectrum antiviral possibilities, will rank right up there w/ IBD. We don't need OM to be a home run, we just need it like a good lead off batter to set up the heavy hitters coming up right behind it.
I will own up that I doubted her big time since I didn't think anybody could have inside information.
All in all, quite a great day for IPIX.
Your hypothesis would keep me in the stock forever. Upfront and milestones would make the share price palatable and the royalties would provide a decent sized investment such as I have with immense yearly dividends if Brilacidin becomes the blockbuster it has the potential to become.
There better be some very hefty royalties involved as well as $100MM up front for a drug that could generate $10B+ per year
Predictions are easy to make but how many are truly based on actual information?
I believe with IPIX nothing is getting out as to whether they have anything going currently with potential partners or govt grants.
I acknowledge that the news regarding the 20 virus govt research of B is quite promising, the Squamus investment could be quite promising, the Kips Bay additional investment is certainly a bit of news that looks promising, the government stating that they need to find a COVID drug that is safe, works against not only viruses but infections as well is positive, the Marburg filovirus spread is quite scary but B has been shown to be effective in initial lab testing per PR LAST YEAR (yet nothing has been done since then to prepare exactly for what is happening today and killing people, possibly in great numbers soon?), the hiring of a BP deal maker appears extremely positive as Leo has shown no aptitude whatsoever tin getting a deal signed for any part of our drug platforms, and the upcoming presentation in Sept appears positive.
I am not questioning that things appear to be coming together in a far, far, far better manner than what seemed to be happening in the first 5 months of the year.
But, it appeared that B was in a perfect storm for success when we started our Covid trial and only later did we find out the FDA tanked our trial with a low dosage, minimal dosing requirement, B was given far too late in the life cycle of Covid to provide any benefit, Russia tested mainly patients way more severe than the trial was supposed to test, and most patients were taking other drugs that were supposed to have kept them out of the trial as they worked against B effectiveness.
I point out the above to show that the value of our positive sounding items above all lay in the details and the details will determine whether they will come to fruition.
I don't mean to scare any new eyes coming to IPIX, our science to date looks extremely promising but we have been saying that now for about 7 years and this investment has mainly brought most of us to our knees financially.
IPIX is still under the thumb of the hedge funds and they ALONE control our stock price. They could tomorrow take it to $.25 or bring it down to $.015 without the bat of an eye. So trying to find technical reasons for our stock rise IMO is foolish.
IPIX isn't dead, but it has a hell of a ways to go to return to good health. I reiterate my point since last November with the terrible price dive, IPIX will not be anywhere near healthy UNTIL we sign some sort of deal that brings in significant funds or we get a major government grant that does the same. At this time, I believe a sale or partnership of some part of our drug platforms is the best shot we have to climb out of the grave we are currently in.
Being somewhat positive is to be expected and that reflects my view of IPIX today, but don't think this is a slam dunk winner yet by any means.
I wonder when they are going to get off their collective asses and put all this research to work? They have had years and yet they haven't given B to even a small trial of patients that were in danger of perishing, not a clinical trial, but just an emergency test to see if B holds up well as clinical testing would indicate. 20 deadly viruses and they are worried about losing a possible few handful of patients when they could possibly find an answer to some virus or viruses that could save thousands?
I would guarantee they would find a great many candidates that had nowhere else to go for treatment. IMO this continual "do nothing but research" BS is just that and until they start moving it past the starting line it continues the spiraling of B with no advancement.
I personally don't look to the government as the solution. It will have to come from a BP joining with IPIX for some part of the B/K platforms to move IPIX forward.
Some praise the constant research into B, while for me all I see is the innate administrative BS which is the government (and big medicine) in taking years to do what should have been accomplished much quicker. I think the milking of money by these outfits in researching is of more importance to them than getting something actually accomplished.
The government did all the testing to date so who will be attending the conference to throw additional money towards B as everyone in govt that has something to do with bacteria and viruses should already know about the broad spectrum capabilities of the drug??
What good did that white paper do IPIX a few years ago that went out to all the world's great virologists? So I give these conference papers and poster reports little to no importance.
I see no great leadership anywhere in govt, science, or business (other than Elon Musk) that is actually trying to advance things on a large scale in a get-it-done manner. Leadership is next to nil as long as the big boys are bringing in the big bucks themselves
If the big boys don't recognize by now the potential of B God help us all.
1MM shares at .04 is only $40K.
Hedge funds can swing this without a second glance so they control the stock price pretty easily. They don't have to do it in one day or with lots of trades, they just take it down on low volume trades and drain the life out of momo players.
I believe the recent news should allow for a deserved nice appreciation in share price but still don't believe hedge funds will let it happen.
The playbook says we get a big pullback tomorrow - my guess is around mid-morning.
Just a way of letting everyone know who is in complete control of the share price.
Thanks for clearing that up for me.
I don't follow this Payer Analysis conversation at all. I take it IPIX paid for a report on which path (via some BP partner) to follow regarding the OM P3 or any other further development of B for that condition.
One, I don't see why Leo can't figure out for himself which is the best deal for IPIX.
Two, if the report is beneficial I don't see how he could possibly put out any information regarding it until he has signed a deal with the BP the Analysis favored. Now once he has signed a deal with a BP, that would be the time for a PR. Not before.
Thus, I don't believe the Payer Analysis is a valid topic of discussion but I could be way off base. Bottom line, i will believe it when I see it.
Excerpts from Squalus Pharma website; https://www.squalusmed.com
Nice to see the solid professional background with COMMERCIAL SUCCESS in spades for both of the founders of Squalus. Makes this endeavor have a lot more meat on the bone than just an idea from newbie inventors. Don't think we will see much of a sit back and wait attitude from these two.
Leadership
Moshe Eshkol
Moshe a solid state physicist, did his PhD. Studies at the Tel Aviv University, has extensive knowledge of numerical simulations, FEA analysis and optical and mechanical design. Moshe led the development of a new type of stent for the treatment of hypertension at Vascular Dynamics. The stent is in advanced clinical trials with the potential to impact over one billion people. Moshe founded and led Asymmetric medical, where he invented the SmartFiber an asymmetric revolutionary fiber optic that redefined the use of fibers in the medical world. The SmartFiber was integrated in various products for the laparoscopy, orthopedic surgery and GYN including collaborations with Flex Inc. and TAG Medical. Moshe is also a veteran of the Israeli Air Force discharged as a Major and continues to be an active pilot.
Gil Shapira
Gil brings forward over 26 years of engineering and product development and management experience, with over 17 years in the surgical laser industry. Gil owns and manages neoLaser, a company he founded in 2012, and led to revenue growth and profitability and a CAGR of 35% from 2014 to 2019. neoLaser has over 800 global installations and performs more than 30,000 surgeries annually in over 30 countries. Previously Gil led product development and marketing at OmniGuide, a successful high-growth laser based medical device spin-off out of the Massachusetts Institute of Technology (MIT). Prior to OmniGuide Gil served as an officer in the Israeli Air Force, with responsibility for management of advanced technology projects. He holds an M.Sc in Electrical Engineering from Tel-Aviv University (Summa Cum Laude), a B.Sc in Electrical Engineering and B.A in Physics from the Technion, Israel Institute of Technology (both Summa Cum Laude) and an MBA from MIT, Sloan School of Management.
So would the customers (I assume hospitals) just be buying the Squalus software since they most likely already have a laser and then pay Squalus on a licensing agreement (such as weekly, monthly, or yearly) or maybe per use each time they use the software? If so, seems like a fairly inexpensive way to be able to have access to a great new technology and may spread worldwide fairly quickly via word of mouth from cancer center to cancer center. Beating a dead horse, but why wouldn't United Cancer Fund help out when they see a potential new cancer treatment that shouldn't be that expensive to throw a few dollars their way? I have always wondered if they actually get much done with their funds and just how organizations go about tapping into them.
Every person in the government (including the FDA, NIH, etc) is for sale at the right price. There are a few exceptions but all in all duty seems to take a back seat to personal gain. Sad state of affairs.
As for IPIX, the only price increase that IMO will not be a result of the games played by those shorting the stock (whether legally or illegally) will be that seen as a result of an outright sale of the company as a whole or a total partnership deal for the entire B and K platforms.
Any other increase, whether for further study, inflow of funds (what good would funds do since they have already studied B to death?), etc. would not generate enough increased investor input to be able to counteract the money thrown against IPIX by those shorting the stock.
Hope Leo is wise enough to realize the only hope left at getting any value out of IPIX is to make a deal and not to wait for the "ultimate" deal but any decent offer.
Would also like to know why an employee was added this year as nothing is happening and thus it seems a waste of money. Salaries of Leo and Harkness should also be brought to a minimum as their duties now seem minimal and their performance to date atrociously bad.
I still believe Brilacidin would be a great gift to the world but whether it ever sees the light of day as an approved drug remains to be seen. Also wonder what defensin mimetic, if any, that DeGrado has been working on over the last decade in his UCSF lab has progressed to commerciality or is nearing that status. Hell of a lot of study for nothing to have come to fruition yet.
With all the study of B to date, if BARDA hasn't seen fit to jump into advancing it then either something is amiss in what we have been led to believe are the wonderful antibacterial and antiviral properties of it or BARDA is a complete clusterf*** of an organization and its biolabs aren't efficient enough to be worthwhile.
.
Tractman, you and I seem to be about the only 2 on this board. I live near UTA where GWTI has their prototype lab. Send me an email if you would like to talk as it is a very interesting story to this stock. petemantx@charter.net
If it can handle a superbug that NO other antibiotic can handle, the price becomes pretty minute to those needing the treatment.
So the medical establishment in USA decided to run a big test on Ivermectin even though it had showed no promising clinical data prior to the trial, just heresay testimony from many "conservative" souces.
So IMO the govt should run a trial AT THEIR EXPENSE as was this Ivermectin trial run since Brilacidin showed positive results when given at a higher dosage and longer dosing period in the recent P2 trial and the Compassionate Use patients.
We will see.
Right now I feel like their is a big wall put up to stop Brilacidin going forward, hope to see something soon to dispel this feeling.